GleamWall
中文EN

MTNB Matinas BioPharma Holdings, Inc.

Pharmaceutical Preparations · NYSE · SEC CIK 1582554 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY58.9%
TTM EPS YoY114.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-147.5%
ROA-98.4%
ROIC (approx.)-535.3%
Asset turnover—

Leverage & solvency

Liabilities / assets33.1%
Debt / equity0.00x
Current ratio1.78x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.95x
Accruals ratio-5.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense———$0$0$0$85,000$2.38M
SG&A expense$1.74M$1.55M$1.94M$1.60M$1.58M$1.84M$1.86M$1.66M
Operating income-$1.74M-$1.55M-$1.94M-$1.60M-$1.58M-$1.84M-$1.95M-$8.47M
Net income-$1.76M-$1.33M-$1.92M-$1.91M-$1.53M-$5.25M-$1.66M-$8.43M
EBITDA-$1.74M-$1.55M-$1.94M-$1.60M-$1.57M-$1.82M-$1.93M-$8.38M
EPS (basic)-9.35-0.21-0.30—-5.93-1.03-0.33—
EPS (diluted)-9.35-0.21-0.30—-5.93-1.03-0.33—
Weighted avg. shares (diluted)950,6126.41M6.41M—362,3885.09M5.09M—
Balance sheet
Cash & equivalents$1.94M$761,000$2.40M$4.00M$5.43M$6.53M$6.92M$7.28M
Current assets$2.12M$1.14M$2.81M$4.08M$5.65M$7.27M$7.55M$8.03M
PP&E, net——$138,000$138,000$156,000$158,000$450,000$468,000
Intangibles$2.26M$2.26M$2.26M$2.26M$2.26M$2.26M$2.26M$2.26M
Total assets$4.38M$3.41M$5.87M$7.21M$9.70M$11.42M$12.04M$12.64M
Current liabilities$1.19M$1.35M$2.13M$1.46M$1.50M$1.78M$2.25M$2.67M
Total liabilities$1.45M$1.61M$2.85M$2.38M$3.23M$3.75M$5.76M$5.05M
Shareholders' equity$2.93M$1.80M$3.02M$4.83M$6.46M$7.67M$6.27M$7.59M
Shares outstanding1.10M6.41M6.41M427,0795.90M5.09M5.09M5.09M
Cash flow statement
Operating cash flow-$1.61M-$1.84M-$1.60M-$1.51M-$1.47M-$2.02M-$2.01M-$3.51M
Investing cash flow———$15,000———$500,000
Financing cash flow$2.79M——$58,000$64,000$1.62M$1.65M-$1,000
Depreciation & amortization$0$0$0$3,000$2,000$12,000$18,000$90,000
Stock-based compensation$100,000$104,000$113,000$217,000$253,000$238,000$315,000$244,000

Free plan shows the latest 8 periods; Pro shows all 55 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.